Hypertension Management: A Paradigm Shift in the Making
Blood pressure control is a critical health issue, yet treatment approaches have been evolving with mixed success.
Editor's Note: This article, originally published in the Cleveland Clinic Journal of Medicine, explores the dynamic landscape of hypertension management and the ongoing quest for better treatment strategies. The original article can be found at https://www.ccjm.org/content/92/8/471.
Dr. George Thomas (https://providers.clevelandclinic.org/provider/george-thomas/4270263) delves into the evolving paradigms of hypertension management, where the focus has shifted from solely controlling blood pressure (BP) to a more holistic approach. The current treatment paradigm recommends a combination of lifestyle changes and medication, with first-line drugs including angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, calcium channel blockers, and diuretics.
But here's where it gets controversial: despite the availability of effective medications, BP control rates have been declining. This trend, exacerbated by the COVID-19 pandemic, highlights the need for improved treatment strategies. The article suggests that a step-up approach to pharmacologic therapy, where multiple medications are added over time, may not be the most effective strategy.
Single-pill combinations (SPCs) offer a promising alternative. SPCs combine two or more medications into a single pill, improving adherence and BP control. Clinical guidelines, such as the 2017 American Society of Cardiology/American Heart Association guidelines and the 2024 European Society of Cardiology guidelines, support the use of SPCs for hypertension. However, real-world utilization remains low, with only 39% of US adults on multiple antihypertensive medications using SPCs.
And this is the part most people miss: the underutilization of SPCs is not due to a lack of effectiveness, but rather a combination of factors. These include ingrained prescribing habits, limited familiarity with SPCs, and concerns about side effects when multiple drugs are combined. Additionally, while generic SPCs are available, there is a lack of triple-drug formulations and SPCs with preferred diuretics like chlorthalidone.
The article suggests that broader adoption of SPCs and expanded formulations could significantly improve hypertension management. Recent research into low-dose SPC therapy has shown promising results, with optimal efficacy and reduced side effects. A notable development is GMRx2, a low-dose triple-drug SPC containing a thiazide-like diuretic, which has been approved by the FDA. Studies show good tolerability and BP reductions with GMRx2, making it a potential first-line treatment.
However, the controversy continues: while low-dose SPC therapy shows promise, concerns about hypotension and side effects remain. The article highlights other novel approaches, such as dual endothelin receptor antagonists (like aprocitentan), aldosterone synthase inhibitors, hepatic angiotensinogen attenuators, device-based treatments (e.g., renal denervation), and cuffless BP measurement devices.
The field of hypertension management is witnessing exciting innovations, but the article emphasizes the importance of not neglecting the fundamentals. Proper BP measurement, adherence to lifestyle changes, and equitable access to care are crucial. As new therapies emerge, the challenge lies in implementing them effectively to benefit those who need them most.
The journey towards optimal hypertension management is ongoing, and the article invites readers to reflect on the evolving paradigms and share their thoughts on the potential controversies and future directions.
